Attovia Therapeutics, Inc. (ATTO)
| Market Cap | 690.70M |
| Revenue (ttm) | 1.44M |
| Net Income | -78.87M |
| EPS | -7.49 |
| Shares Out | 45.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,873 |
| Open | 16.00 |
| Previous Close | 15.81 |
| Day's Range | 14.20 - 16.00 |
| 52-Week Range | 12.94 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.20 (+185.53%) |
| Earnings Date | Nov 9, 2026 |
About ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ATTO stock is "Strong Buy." The 12-month stock price target is $43.2, which is an increase of 185.53% from the latest price.
News
Attovia price target raised to $34 from $30 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Attovia (ATTO) to $34 from $30 and keeps a Buy rating on the shares.
Attovia price target raised to $40 from $39 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Attovia (ATTO) to $40 from $39 and keeps an Overweight rating on the shares.
Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in patien...
Attovia Therapeutics Quarterly report: Q3 2026
Attovia Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Attovia Therapeutics Earnings release: Q3 2026
Attovia Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Attovia Therapeutics Transcript: KOL event & Study update
Single-dose ATTO-1310 produced durable itch and skin-lesion improvements through week 12 in chronic pruritus and high-itch AD, supporting quarterly dosing. Phase II ATTUNE studies are expected to dose first patients in H1 2027.
Attovia Therapeutics Press release: KOL event & Study update
Attovia Therapeutics issued a press release on November 5, 2026, disclosing material business information to investors.
Attovia Therapeutics Slides: KOL event & Study update
Attovia Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatit...
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biot...
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for ...
Attovia Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted rapid progress in developing modular nanobody-based biologics for immune-mediated diseases, with ATTO-1310 showing strong early efficacy and safety in chronic itch. Upcoming phase II trials target large unmet needs, while the pipeline expands into bispecific and trispecific assets, all supported by a robust financial position.
Attovia Therapeutics Slides: Corporate presentation
Attovia Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 7, 2026.
Attovia reports Q2 EPS ($4.88), consensus ($4.61)
“Following the successful completion of our upsized IPO, Attovia (ATTO) enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creatin...
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
Attovia Therapeutics Quarterly report: Q2 2026
Attovia Therapeutics has published its Q2 2026 quarterly earnings report on September 2, 2026.
Attovia Therapeutics Earnings release: Q2 2026
Attovia Therapeutics released its Q2 2026 earnings on September 2, 2026, summarizing the period's financial results.
Attovia initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target
Attovia initiated with an Outperform at Leerink
Leerink initiated coverage of Attovia (ATTO) with an Outperform rating and $52 price target
Attovia initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz initiated coverage of Attovia (ATTO) with a Buy rating and $30 price target The firm says the company has a “partially derisked” opportunity across large chronic…
Attovia initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Attovia (ATTO) with an Overweight rating and $39 price target The company’s focus on “de-risked targets” positions it path to blockbuster opportunities in chronic ...
Attovia initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target The firm believes the company’s Attobody platform, which designs biologics against validated targets, wi...
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for i...
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, ...
Attovia opens at $21.00, IPO priced at $17.00
Attovia (ATTO) priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00…